Unique in its approach, the Amyloidosis Center provides exceptional care for patients with all forms of systemic and localized amyloidosis through the support of laboratory and clinical research
Support Amyloidosis Research & Clinical Innovation
Our laboratory and clinical research is supported by grants from the government and from foundations, and by individual donations. These are vital for support of our mission to help us in our quest for a cure for amyloidosis.
Researchers and Physicians
VJHemOnc Amyloidosis Sessions
International Symposium on Amyloidosis
This gathering of leading experts in the field of amyloidosis is held biennially at different locations around the world. This year, the four-day meeting was held in Heidelberg, Germany and comprised 25 lectures, 71 oral presentations, 309 poster presentations and 8 satellite symposia. There was notable growth in the number of participants and their countries […]
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Happy Retirement to Dr. Lawreen Connors and Dr. Haili Cui!
Happy retirement to Dr. Lawreen Connors and Dr. Haili Cui! Dr. Connors has led the Gerry Research Laboratory with distinction for many decades, and Dr. Cui has been the manager of histopathology in the Amyloidosis Center for 11 years. We will miss you both tremendously!
National Doctor’s Day
Today is National Doctors’ Day, and we’d like to take a moment to say thank you to the incredible physicians that make up our Multidisciplinary Team at the BU Amyloidosis Center! #nationaldoctorsday #amyloidosis
Congratulations Dr. Siddiqi!
The outstanding service of Dr. Omar Siddiqi has been honored by The Boston University School of Medicine with the "Educator of the Year" award! Congratulations Dr. Siddiqi!
Intellia’s first CRISPR gene editing therapy shows promise in small study
"Intellia Therapeutics has moved one step closer to its ambition of creating one-and-done gene-editing treatments for people with genetic diseases. Last August, the Cambridge company and its partner, Regeneron Pharmaceuticals, published a landmark study showing that even low doses of their one-time treatment based on CRISPR-Cas9 technology could dramatically reduce levels of a disease-causing protein […]